Literature DB >> 22761268

Comprehensive treatment of Huntington disease and other choreic disorders.

Carlos Singer1.   

Abstract

The management of choreic disorders presents significant challenges, including identifying the etiology of the disorder, treating and preventing motor symptoms, and managing a range of other neurologic and behavioral complications. Chorea may occur in several neurodegenerative, genetic, or drug-related conditions, and a thorough diagnostic evaluation is needed to identify the specific underlying causes. Some choreic disorders have specific treatable underlying etiologies, such as vitamin B(12) deficiency or drug-induced dyskinesia. Autoimmune disorders such as Sydenham chorea may be treated with penicillin, corticosteroids, intravenous immunoglobulin, or plasma exchange. Heredodegenerative choreas such as Huntington disease often respond to treatment with tetrabenazine or amantadine. Many other agents may be used nonspecifically for symptom control, including benzodiazepines, neuroleptics, and antiepileptic medications. In addition to motor symptoms, patients with Huntington disease or other choreic disorders often experience increasing depression, bradykinesia, cognitive impairment, aggressive behaviors, and other complications as the disease progresses. Caring for the caregiver is also a significant concern in the long-term treatment of choreic disorders.

Entities:  

Mesh:

Year:  2012        PMID: 22761268     DOI: 10.3949/ccjm.79.s2a.06

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  10 in total

1.  Psychosis with Huntington's disease: role of antipsychotic medications.

Authors:  Jonathan Ding; Amin Muhammad Gadit
Journal:  BMJ Case Rep       Date:  2014-08-19

2.  Soluble N-terminal fragment of mutant Huntingtin protein impairs mitochondrial axonal transport in cultured hippocampal neurons.

Authors:  Jun Tian; Ya-Ping Yan; Rui Zhou; Hui-Fang Lou; Ye Rong; Bao-Rong Zhang
Journal:  Neurosci Bull       Date:  2013-12-21       Impact factor: 5.203

3.  Reliability and Validity of the HD-PRO-TriadTM, a Health-Related Quality of Life Measure Designed to Assess the Symptom Triad of Huntington's Disease.

Authors:  Nicholas R Boileau; Julie C Stout; Janes S Paulsen; David Cella; Michael K McCormack; Martha A Nance; Samuel Frank; Jin-Shei Lai; Noelle E Carlozzi
Journal:  J Huntingtons Dis       Date:  2017

Review 4.  Patient-derived iPSC modeling of rare neurodevelopmental disorders: Molecular pathophysiology and prospective therapies.

Authors:  K R Sabitha; Ashok K Shetty; Dinesh Upadhya
Journal:  Neurosci Biobehav Rev       Date:  2020-12-25       Impact factor: 8.989

5.  HD-PRO-TRIAD™ Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease.

Authors:  Noelle E Carlozzi; David Victorson; Victor Sung; Jennifer L Beaumont; Wendy Cheng; Brian Gorin; Mei Sheng Duh; David Samuelson; David Tulsky; Sandra Gutierrez; Cindy J Nowinski; Allison Mueller; Vivienne Shen; Samuel Frank
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-04-14

6.  Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.

Authors:  David Victorson; Noelle E Carlozzi; Samuel Frank; Jennifer L Beaumont; Wendy Cheng; Brian Gorin; Mei Sheng Duh; David Samuelson; David Tulsky; Sandra Gutierrez; Cindy J Nowinski; Allison Mueller; Vivienne Shen; Victor Sung
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2014-04-14

Review 7.  Palliative Care in Huntington Disease: Personal Reflections and a Review of the Literature.

Authors:  Christopher G Tarolli; Amy M Chesire; Kevin M Biglan
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-04-11

Review 8.  Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease.

Authors:  Thirunavukkarasu Velusamy; Archana S Panneerselvam; Meera Purushottam; Muthuswamy Anusuyadevi; Pramod Kumar Pal; Sanjeev Jain; Musthafa Mohamed Essa; Gilles J Guillemin; Mahesh Kandasamy
Journal:  Oxid Med Cell Longev       Date:  2017-01-12       Impact factor: 6.543

9.  Using a Clinical Formulation to Understand Psychological Distress in People Affected by Huntington's Disease: A Descriptive, Evidence-Based Model.

Authors:  Maria Dale; Ashleigh Wood; Nicolò Zarotti; Fiona Eccles; Sarah Gunn; Reza Kiani; Amanda Mobley; Noelle Robertson; Jane Simpson
Journal:  J Pers Med       Date:  2022-07-27

10.  Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data.

Authors:  Christoph Ohlmeier; Kai-Uwe Saum; Wolfgang Galetzka; Dominik Beier; Holger Gothe
Journal:  BMC Neurol       Date:  2019-12-10       Impact factor: 2.474

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.